Mr. Fruendt joined SenesTech in 2022 and has overseen the Company's development and launch of its revolutionary new product, Evolve®, across multiple retail and professional channels. In addition, to further support this transition, the Board has appointed Dr. Jamie Bechtel, current Chair of the Board, to the newly created role of Interim Executive Chair. In this role, Dr. Bechtel will partner with management to support strategic alignment, execution discipline, and clear communication between the Board and ...

Core Insights - SenesTech, Inc. has appointed Sarah Mann and the Belize Raptor Center as the new international distributor for Evolve® Rat Birth Control, aimed at managing rodent populations in Belize [1][2] - The introduction of Evolve Rat in Belize is a response to the ecological threats posed by unregulated rodenticides, which have led to secondary wildlife poisonings [2][3] - A grassroots education campaign has been launched to inform the public about the dangers of traditional rodenticides and promote fertility control as a humane alternative [3][4] Company Overview - SenesTech is focused on creating healthier environments through humane management of animal pest populations via fertility control, with Evolve Rat Birth Control being a key product [6] - The company aims to enhance pest management programs while reducing reliance on traditional poisons, contributing to cleaner cities and healthier communities [6] Market Context - Belize's biodiversity is under threat from the increased use of rodenticides, prompting the need for sustainable solutions like Evolve Rat Birth Control [2][4] - The partnership with local conservationists reflects a growing trend of adopting fertility control methods in integrated pest management programs globally [4]

Core Insights - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] Group 1 - The article suggests that users may face blocks if they have ad-blockers enabled, indicating a need to disable them for proper access [1]

Financial Data and Key Metrics Changes - The company reported record quarterly revenues of $690,000, representing a 43% increase year-over-year and a 10% increase sequentially [17] - Gross margins remained strong at 63%, with gross profit increasing to $433,000 from $315,000 [19] - Adjusted EBITDA loss was the best in the company's history at $1.2 million, compared to $1.4 million in the previous year [7][20] Business Line Data and Key Metrics Changes - Evolved revenue increased by 77% and accounted for 85% of total sales in Q3 [17] - E-commerce sales represented 54% of total revenue, up 55% year-over-year [17][18] - Municipal revenue grew 139% year-over-year, driven by deployments in major cities [11][18] Market Data and Key Metrics Changes - Retail sales surged by 254% year-over-year, primarily due to expanded adoption through Ace Hardware and Bradley Caldwell [11][18] - Pest management professionals (PMP) accounted for 19% of sales, up 29% year-over-year and 72% sequentially [18][14] Company Strategy and Development Direction - The company aims to achieve profitability through high-margin revenue growth and efficient expense management [6][8] - Expansion into brick-and-mortar retail is being pursued, with discussions ongoing for test deployments in Lowe's stores [24] - The company is focusing on increasing production capacity and operational efficiency to meet future demand [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the cash position of over $10 million, indicating a potential path to profitability without further equity offerings [8][20] - The adoption of the evolved rodent birth control solution is seen as a game-changer, with a large addressable market and regulatory tailwinds [22] Other Important Information - The company faced legal challenges from Levitech regarding alleged IP infringement, which management described as baseless [34] - Recent field trials in Somerville and Cambridge are progressing well, with expectations for future orders based on positive results [35] Q&A Session Summary Question: Will the company's products be available in Lowe's brick-and-mortar stores? - The company is in discussions for a test deployment in about 100 stores, with expectations for late Q2 [24] Question: What growth is expected from PMP-driven sales? - PMP is a key growth channel, with significant growth anticipated as awareness of birth control in pest management increases [25] Question: How much of the revenue was from e-commerce? - E-commerce accounted for 54% of quarterly revenue, consistent with previous quarters [26] Question: Is there a plan to adjust pricing for Evolve? - The company is comfortable with the current pricing strategy but may consider discounts for large orders in the future [27] Question: What is the progress in international markets? - The company received approval for distribution in New Zealand and is working on obtaining approvals in other countries [29][30] Question: Can you provide details on the legal expenses? - The company is facing a lawsuit from Levitech, which management believes is an attempt to hinder their business [34] Question: What revenue is expected from recent field trials? - It is too early to project revenues, but positive results from trials are expected to lead to future orders [35]

Revenue and Sales Performance - Revenues for Q3 2025 were $690,000, a 43% increase from $482,000 in Q3 2024, driven primarily by Evolve product sales [103]. - Evolve product sales accounted for approximately 85% of Q3 2025 revenues, up from 69% in Q3 2024, indicating strong market adoption [105]. - For the nine months ended September 30, 2025, revenues were $1.8 million, a 33% increase from $1.356 million in the same period of 2024 [103]. - Evolve product sales represented approximately 83% of revenues for the nine months ended September 30, 2025, compared to 63% in the same period of 2024 [106]. Profitability and Loss - Gross profit for Q3 2025 was $433,000, representing a margin of 62.8%, compared to $315,000 and a margin of 65.4% in Q3 2024 [110]. - The net loss for Q3 2025 was $1.298 million, a 14% improvement compared to a net loss of $1.513 million in Q3 2024 [103]. - The company incurred a net loss of $1.3 million for Q3 2025, continuing to rely on equity sales for funding operations [118]. Operating Expenses - Operating expenses for Q3 2025 totaled $1.78 million, a 4% decrease from $1.86 million in Q3 2024 [103]. - Research and development expenses for Q3 2025 were $400,000, a decrease of $51,000 (11.3%) from $451,000 in Q3 2024, primarily due to cost containment efforts [112]. - For the nine months ended September 30, 2025, research and development expenses totaled $1.2 million, down $43,000 (3.3%) from $1.3 million in the same period of 2024, driven by overall reductions in spending [113]. - Selling, general and administrative expenses for Q3 2025 were $1.4 million, consistent with Q3 2024, with increases in legal fees and franchise fees offsetting cost containment efforts [114]. - For the nine months ended September 30, 2025, selling, general and administrative expenses increased to $4.5 million, up $131,000 (3.0%) from $4.4 million in the same period of 2024, primarily due to higher legal fees [115]. Cash Flow and Financing - Cash flows from financing activities for the nine months ended September 30, 2025, included net proceeds of $10.5 million from warrant exercises and $2.7 million from common stock issuance [131]. - Cash used in investing activities for the nine months ended September 30, 2025, totaled $3.0 million for held-to-maturity investments and $125,000 for property and equipment purchases [129]. - The Warrant Inducement Transaction resulted in the issuance of 1,458,872 shares of common stock at an exercise price of $4.15 per share, generating gross proceeds of $6.3 million [132]. - The new warrants issued relate to 2,188,308 shares of common stock with an exercise price of $5.25 per share, expiring 15 months after the effective date of the resale registration statement [132]. - Placement agent warrants were issued to purchase up to 72,944 shares of common stock at an exercise price of $5.4219 per share [132]. Financial Position and Future Outlook - As of September 30, 2025, the company reported an accumulated deficit of $140.7 million and cash and cash equivalents totaling $10.2 million [119]. - The company expects cash and cash equivalents, along with anticipated revenue, to be sufficient to fund operations for the next 12 months [120]. - The company believes existing cash and investments will be sufficient for the foreseeable future [133]. - The company’s ability to continue as a going concern will depend on generating sufficient revenues, reducing operating costs, or obtaining additional funding if break-even or profitability is not achieved [133]. Market Opportunity - The market opportunity for non-poison rodent control is significant and growing, driven by regulatory restrictions on traditional rodenticides [102]. Accounting Policies - There have been no material changes to critical accounting policies and estimates as disclosed in the Annual Report for the year ended December 31, 2024 [134]. - No quantitative or qualitative disclosures about market risk were applicable [135].

Revenue Growth - Revenues increased by 43% to $690,000 in Q3 2025, a record for the company, compared to $482,000 in Q3 2024[4] - Evolve® Rodent Birth Control product sales grew 77% year-over-year, now representing 85% of total revenue[4] - Municipal revenue grew 139% year-over-year due to expanded deployments in cities like New York and Chicago[4] - Retail revenue increased by 254% year-over-year, driven by expanded adoption by Ace Hardware and follow-on orders from Bradley Caldwell[4] - E-commerce revenue rose 55% year-over-year, with significant growth in Amazon sales and other platforms[4] - Pest management professionals contributed to a 29% year-over-year revenue increase, representing nearly 20% of total revenue[5] Financial Performance - Adjusted EBITDA loss improved to $1.2 million in Q3 2025, compared to $1.4 million in the same quarter of the prior year[4] - Net loss for Q3 2025 was $1.3 million, an improvement from $1.5 million in Q3 2024[4] - The gross profit margin was 62.8%, in line with expectations[4] Cash Position - Cash and short-term investments totaled $10.2 million, providing a solid operating runway for the foreseeable future[4]

Core Insights - SenesTech, Inc. reported a 43% increase in revenues to $690,000 for Q3 2025, marking a record for the company, with Evolve® Rodent Birth Control product sales growing 77% year-over-year, now accounting for 85% of total revenue [7][4][1] Financial Highlights - Revenues increased to $690,000 from $482,000 in Q3 2024, representing a 43% growth [7] - Gross profit margin was reported at 62.8% [7] - Net loss for Q3 2025 was $1.3 million, an improvement from a loss of $1.5 million in Q3 2024 [7] - Adjusted EBITDA loss improved to $1.2 million, compared to $1.4 million in the same quarter of the prior year [7] - Cash and short-term investments totaled $10.2 million, providing a solid operating runway [7] Operational and Strategic Highlights - Evolve Rat and Evolve Mouse products, launched in 2024, grew 77% year-over-year and are the largest revenue drivers, representing 85% of total revenue [7] - E-commerce revenue increased by 55% year-over-year, with significant growth in Amazon sales [7] - Municipal revenue grew 139% year-over-year, driven by expanded deployments in cities like New York and Chicago [7] - Retail revenue surged 254% year-over-year, largely due to increased adoption by Ace Hardware and follow-on orders from Bradley Caldwell [7] - Revenue from pest management professionals increased by 29% year-over-year, contributing nearly 20% of overall revenue for Q3 2025 [7]

Core Insights - SenesTech, Inc. has launched its Evolve® Rat Birth Control® product on Lowes.com, marking a significant milestone in consumer accessibility and retail distribution [1][4][5] - Evolve Rat is the first soft bait targeting rat reproduction, providing a humane and sustainable solution to manage rat populations without poisons [2][4] - The partnership with Lowes, which has over 1,700 stores and $11 billion in online sales, is expected to enhance brand visibility and accelerate adoption among consumers [3][4] Company Overview - SenesTech focuses on humane pest management through fertility control, aiming to create healthier environments by reducing reliance on traditional poisons [5] - The company’s mission includes creating cleaner cities and healthier communities with effective and sustainable products [5] Market Opportunity - The launch on Lowes.com is seen as a strategic move to expand Evolve Rat's retail footprint, potentially leading to stronger revenue streams and increased market presence [4][8] - The product addresses a critical issue in pest management by targeting the root cause of population growth rather than merely increasing death rates [4][7]

Core Insights - SenesTech, Inc. will report its third quarter 2025 financial results on November 10, 2025, after market close, followed by a conference call at 5:00 p.m. Eastern time to discuss the results [1][2] Company Overview - SenesTech is focused on humane pest management through fertility control, having developed ContraPest®, the only U.S. EPA-registered contraceptive for both male and female rats, along with Evolve Rat and Evolve Mouse, which are EPA-designated minimum risk contraceptives for rodents [3] Conference Call Details - The conference call on November 10, 2025, will be accessible via a live webcast, with a replay available for 90 days on the company's Investor Relations website [2]

Core Insights - SenesTech, Inc. has launched a pilot program in Swampscott, Massachusetts, utilizing Evolve® Rat Birth Control to manage rat populations humanely without harsh chemicals [1][4] - The initiative aims to provide a sustainable solution to pest control, focusing on prevention rather than short-term elimination [4] Company Overview - SenesTech specializes in fertility control for pest management, having developed products like ContraPest and Evolve Rat, which are designed to be humane, effective, and sustainable [5] - The company’s mission is to improve public health by managing animal pest populations through innovative fertility control methods [5] Pilot Program Details - The pilot program is a collaboration with Speak Up for Animals and local advocate Debora Norman, aiming to protect public health while minimizing risks to children, pets, and wildlife [2] - Evolve Rat works by controlling rat reproduction, addressing the root cause of infestations, and has shown success in various settings across the country [3] Community Impact - Swampscott is one of the first communities in Massachusetts to implement this innovative pest control method, reflecting a commitment to safer and more responsible rodent management [4] - The pilot will be monitored closely, with potential expansion to additional neighborhoods in 2026 if successful [4]